I’ve said before that the opt-out public option was politically savvy. I still believe that. We get a reasonably robust, nationwide public option. Politicians on
Yesterday I addressed the relative amounts that the pharmaceutical industry spends on research and development as opposed to other expenses. But there’s still another way
We have argued that increased enforcement of competition laws against insurers without similar efforts against providers could have perverse consequences without a public option. And
The fundamental problem in health care in the U.S. is that we spend so much to get so little. The current health reform effort is
the health services research blog
Work posted here under copyright © of the authors • Details on the Site Policies page
